Volume 11,Issue 1
Study on the Effects of Curosurf Combined with Budesonide on Blood Gas Analysis Indices and Complications in the Treatment of Respiratory Distress Syndrome in Premature Infants
Objective: To investigate the effects of Curosurf combined with budesonide on blood gas indices and complications in the treatment of respiratory distress syndrome in premature infants. Methods: From October 2021 to October 2023, 60 premature infants with respiratory distress syndrome were selected from our hospital and divided into a control group and an observation group, with 30 infants in each group. The value of the treatment was compared between the two groups. Results: The observation group had lower mechanical ventilation time, hospital stay, PaCO2 level, and complications than the control group (p < 0.05). The pH, PaO2, OI index levels, and total effective rate were higher in the observation group than in the control group (p < 0.05). Conclusion: The combination of Curosurf and budesonide in the treatment of respiratory distress syndrome in premature infants can effectively optimize blood gas analysis indices and improve treatment outcomes. It is worthy of clinical promotion.
[1] Wu Z, 2021, The Influence of BiPAP Combined with Bovine Lung Surfactant on Blood Gas Indicators in Premature Infants with Respiratory Distress Syndrome. Contemporary Medicine, 27(28): 81–83.
[2] Dargaville P, Kamlin C, Orsini F, et al., 2021, Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants with Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA, 326(24): 2478–2487.
[3] De Luca D, 2021, Respiratory Distress Syndrome in Preterm Neonates in the Era of Precision Medicine: A Modern Critical Care-Based Approach. Pediatric and Neonatology, 62(S1): S3–S9.
[4] Abdel-Latif M, Davis P, Wheeler K, et al., 2021, Surfactant Therapy via Thin Catheter in Preterm Infants with or at Risk of Respiratory Distress Syndrome. Cochrane Database of Systematic Reviews, (5): CD011672.
[5] Tian Y, Guo L, 2023, Clinical Effect of Budesonide and Poractant Alfa Injection Combined with High-Frequency Oscillatory Ventilation Superimposed on Conventional Ventilation in the Treatment of Severe Respiratory Distress Syndrome in Premature Infants. Clinical Research and Practice, 8(9): 58–60.
[6] Ren S, Xia M, 2020, Analysis of the Effect of Curosurf in the Treatment of Respiratory Distress Syndrome in Premature Infants. Chinese Community Doctors, 36(30): 59–60.
[7] Zhou C, Xu Q, Liu L, et al., 2019, Study on the Efficacy of Curosurf Injection through a Thin Catheter Combined with Positive Airway Pressure Ventilation in the Treatment of Respiratory Distress Syndrome in Premature Infants. China Medical Equipment, 16(1): 77–81.
[8] Anonymous, 2017, “European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome (2016 Edition)” Published. China Medical Information Herald, 32(7): 9.
[9] Zhang Y, Gao K, 2024, Clinical Effect of Noninvasive High-Frequency Oscillatory Ventilation in the Treatment of Premature Infants with Neonatal Respiratory Distress Syndrome and Its Influence on Blood Gas Analysis Indicators. Clinical Research and Practice, 9(3): 83–86 + 91.
[10] van Kaam A, Niemarkt H, Onland W, 2023, Timing of Surfactant Treatment in Respiratory Distress Syndrome. Seminars in Fetal and Neonatal Medicine, 28(6): 101495.
[11] Krajewski P, Pomianek T, Truszkowski K, et al., 2022, Respiratory Distress Syndrome in Preterm Infants: Possible Impact of Surfactant Application Techniques. Ginekologia Polska, 93(9): 750–755.
[12] Sibrecht G, Kearl C, Borys F, et al., 2023, Surfactant Therapy Guided by Tests for Lung Maturity in Preterm Infants at Risk of Respiratory Distress Syndrome. Cochrane Database of Systematic Reviews, 10(10): CD013158.
[13] Zhang T, 2023, Clinical Efficacy of Budesonide Suspension Combined with Poractant Alfa Injection in the Treatment of Severe Respiratory Distress Syndrome in Premature Infants and Its Impact on Prognosis. Rational Drug Use in Clinic, 16(3): 128–131.
[14] Cai L, Li X, Zhang S, et al., 2020, Observation on the Efficacy of Budesonide Combined with Curosurf in the Treatment of Bronchopulmonary Dysplasia in Premature Infants. Chinese Journal of New Clinical Medicine, 13(1): 78–82.
[15] Zhu C, 2019, Comparative Study on the Clinical Efficacy of Curosurf and Calsurf in the Treatment of Respiratory Distress Syndrome in Premature Infants. Clinical Medical Engineering, 26(3): 341–342.